Zai Lab Limited (ZLAB)

Market Cap	2.58B
Revenue (ttm)	441.63M
Net Income (ttm)	-206.81M
Shares Out	111.27M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,464,144
Open	23.16
Previous Close	24.80
Day's Range	21.68 - 24.44
52-Week Range	21.68 - 44.34
Beta	0.85
Analysts	Buy
Price Target	57.22 (+147.17%)
Earnings Date	Nov 6, 2025

About ZLAB

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 1,869
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB
• Website: https://www.zailaboratory.com

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ZLAB stock is "Buy." The 12-month stock price target is $57.22, which is an increase of 147.17% from the latest price.

Price Target

$57.22

(147.17% upside)

Analyst Consensus: Buy